Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | CLK2 | P49760 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | GSK3B | P49841 | 2/20 | 0.63 |
| ▸ | TOP2A | P11388 | 6/20 | 0.60 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393776 | 1.00 | KDM4E (0.65) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL541514 | 0.99 | KDM4E (0.64) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL541515 | 0.99 | KDM4E (0.64) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL28424222 | 0.99 | KDM4E (0.64) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| Fluoride SCHEMBL5143207 | 0.98 | KDM4E (0.63) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL5455055 | 0.98 | KDM4E (0.63) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| Boric Acid SCHEMBL1155094 | 0.97 | KDM4E (0.62) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL3558935 | 0.97 | KDM4E (0.62) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL4368210 | 0.97 | KDM4E (0.62) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL12427273 | 0.95 | KCNH2 (0.60) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115322191-B | Synthetic method of moxifloxacin hydrochloride | 苏州汉德创宏生化科技有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-114539244-B | Preparation method of moxifloxacin hydrochloride | 沈阳药科大学 | 2023-04-14 | — | — | CN | claimed |
| CN-115536658-A | Preparation method of moxifloxacin hydrochloride monohydrate | 天方药业有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-115322191-A | Method for synthesizing moxifloxacin hydrochloride | 苏州汉德创宏生化科技有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-114539244-A | Preparation method of moxifloxacin hydrochloride | 沈阳药科大学 | 2022-05-27 | — | — | CN | claimed |
| CN-111233858-B | Preparation method of moxifloxacin hydrochloride | 常州方圆制药有限公司 | 2022-05-24 | — | — | CN | claimed |
| CN-114249722-A | Preparation method of moxifloxacin hydrochloride | 常州方圆制药有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114105973-A | Quinolone analogue and preparation method and application thereof | 常州方圆制药有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-112759590-B | Preparation method of moxifloxacin | 内蒙古源宏精细化工有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-110627768-B | Preparation method of moxifloxacin degradation impurity J | 扬子江药业集团有限公司 | 2021-11-09 | — | — | CN | claimed |
| US-20060252770-A1 | Novel crystalline forms of gatifloxacin and processes for preparation | TAVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-11-09 | — | — | US | claimed |
| EP-1651630-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF MOXIFLOXACIN HYDROCHLORIDE | Matrix Laboratories Ltd (IN) | 2006-05-03 | — | — | EP | claimed |
| WO-2006004561-A1 | PROCESS FOR THE PREPARATION OF GATIFLOXACIN AND REGENERATION OF DEGRADATION PRODUCTS | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2006-01-12 | — | — | WO | claimed |
| US-20050080264-A1 | Novel synthesis of gatifloxacin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-04-14 | — | — | US | claimed |
| WO-2005012285-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF MOXIFLOXACIN HYDROCHLORIDE | MATRIX LABORATORIES LTD (IN) | 2005-02-10 | — | — | WO | claimed |
| EP-1485097-A1 | CRYSTALLINE FORMS OF GATIFLOXACIN AND PROCESSES FOR PREPARATION | Teva Pharmaceutical Industries Limited (IL) | 2004-12-15 | — | — | EP | claimed |
| EP-1478642-A1 | SYNTHESIS OF GATIFLOXACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-24 | — | — | EP | claimed |
| US-20040171621-A1 | Novel crystalline forms of gatifloxacin and processes for preparation | TEVA PHARMACEUTICALS USA, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2004069825-A1 | SYNTHESIS OF GATIFLOXACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-19 | — | — | WO | claimed |
| WO-2004054583-A1 | CRYSTALLINE FORMS OF GATIFLOXACIN AND PROCESSES FOR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-07-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252770-A1 | Novel crystalline forms of gatifloxacin and processes for preparation | GATD3, CRYAB, CRYZ | KDM4E 1732/4885HPGD 2478/4885KCNH2 3330/4885 |
| US-20050080264-A1 | Novel synthesis of gatifloxacin | GATD3, ATIC, PDE7A | KDM4E 639/4885HPGD 1829/4885KCNH2 2731/4885 |
| US-20040171621-A1 | Novel crystalline forms of gatifloxacin and processes for preparation | GATD3, CRYAB, CRYZ | KDM4E 1732/4885HPGD 2478/4885KCNH2 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.